A b s t r a c t
The most significant side effect of warfarin treatment is an increased risk of bleeding. 1 Outcomes associated with major bleeding in patients taking warfarin are worse than in patients not taking warfarin. 2 International normalized ratio (INR) fluctuations are common because of drug interactions that modify warfarin metabolism, 3, 4 changes in dietary vitamin K intake, 5 or unintentional errors in warfarin dosing. Close monitoring of INR is necessary to avoid both underand overanticoagulation. 6, 7 INR higher than 4 has been associated with an increased risk of bleeding, 8 and the risk of intracranial hemorrhage increases approximately 2-fold for every 1 unit rise in INR. 9 INR greater than 9 is associated with a particularly high risk of bleeding, with up to 20% of patients with INR higher than 9 bleeding within the next week, 10 20-fold higher than patients with INR lower than 9. 11 Well-controlled trials of warfarin have reported an annual risk of bleeding of about 0.5% per year, but real-world studies have found bleeding risks up to 6-fold higher. 12 Studies on correcting excessive anticoagulation with warfarin typically evaluated outpatients only and often excluded patients based on comorbidities, other medications, age, and other factors. 10, [13] [14] [15] [16] [17] Current guidelines to correct excess vitamin K antagonist (VKA)-associated anticoagulation in patients with INR higher than 10 and with no evidence of bleeding recommend giving vitamin K, and recommend 4-factor prothrombin complex concentrate rather than plasma for major VKAassociated bleeding. 18 Vitamin K treatment response has not been evaluated in hospitalized patients with INR higher than 9. We reviewed 162 patients, including both outpatients and inpatients, with an INR higher than 9, and describe herein their bleeding rates, bleeding risk factors, presence of Upon completion of this activity you will be able to:
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comorbidities, and response to different treatment modalities to reverse the warfarin effect.
Materials and Methods
The study was approved by the University of Washington (Seattle) human subjects office. A retrospective analysis was performed of patient charts with INR values higher than or equal to 9 during the period January 1, 2008, to June 10, 2009 . Inpatients and outpatients were included and incomplete charts were excluded, resulting in a total of 162 patients in the study.
Data Collection
Data included the following: gender, age, reason for admission, INR collection date, initial INR result, and where available, INR result 24 hours after treatment, patient location, anticoagulation indication and duration, warfarin dose, platelet count, history of bleeding, chronic heart failure, renal failure, stroke, hypertension, cancer, and alcohol use. Alcohol use was defined as the intake of 1 or more alcoholic beverages per day. Treatments included warfarin cessation, vitamin K administration, and plasma infusion. One patient with trauma received recombinant factor VII in addition to plasma, and none of the patients received factor concentrates.
Statistical Analysis
A logistic model was used to estimate the effect of several predictors on the probability of bleeding. The relationship between the predictors and the occurrence of bleeding was assumed to follow a nonlinear, logistic function based on the weights of the 10 variables used to predict the probability of bleeding, namely, male sex, age, renal failure, congestive heart failure, hypertension, alcohol use, bleeding history, cancer, stroke, and warfarin dose (in log scale). Results are given as the mean ± standard deviation (SD) unless otherwise noted. The unpaired t test was used to determine individual differences between groups.
Results

Patient Characteristics
Of 162 patients with INR higher than 9, 36 (22%) were outpatients and 126 (78%) were inpatients. ❚Table 1❚ shows anticoagulant and fibrinolytic therapy in patients with INR higher than 9. All of the outpatients with INR higher than 9 were receiving warfarin. Of the inpatients with INR higher than 9, 37% were receiving warfarin; 15%, direct thrombin inhibitors; 3%, tissue plasminogen activator; and 45% were not receiving any anticoagulant or fibrinolytic therapy. Patients with INR higher than 9 receiving warfarin were on average 59 years old, with a mean INR of 10.6 ± 1.3. Patients with INR higher than 9 not receiving warfarin were on average 50 years old, with a mean INR of 11.0 ± 1.3. The lower average age of patients with INR higher than 9 not receiving warfarin primarily reflects the population of patients with trauma with INR higher than 9 with an average age of 30 years.
Diagnosis, Bleeding, Treatment, and Mortality in Patients Not Receiving Warfarin
All patients not receiving warfarin with INR higher than 9 were inpatients. ❚Table 2❚ shows the primary diagnosis and number of patients with reported bleeding. The majority of patients (71%) not receiving warfarin who had an INR higher than 9 were also not receiving any other anticoagulant or fibrinolytic therapy. These patients typically had some form of liver failure, shock, or trauma. Of the patients with acute or chronic liver failure and INR higher than 9, 46% had bleeding, typically treated with blood products, and 64% died. All patients undergoing liver transplantation with INR higher than 9 reported bleeding and were treated with blood products, of whom 18% died. Patients were admitted with shock and INR HIT, heparin-induced thrombocytopenia; INR, international normalized ratio. * Thrombosis included ischemic stroke (n = 3), intracardiac thrombosis/disseminated intravascular coagulation (n = 1), limb ischemia (n = 3), and massive pulmonary embolism (n = 2).
higher than 9 for a number of reasons, including resuscitation after cardiac arrest, sepsis, heart failure, and drug overdose. Of patients with shock, 43% were reported to have bleeding, which was treated with blood products, but 90% died. Essentially all patients with trauma with INR higher than 9 had bleeding, of whom most were treated with blood products, and 1 with plasma and recombinant factor VIIa, but all died. Overall, INR higher than 9 in patients not receiving an anticoagulant was a bad prognostic sign; of these, 67% experienced bleeding and 74% died. The patients diagnosed with heparin-induced thrombocytopenia and INR higher than 9 were all receiving a direct thrombin inhibitor (3 received argatroban and 16 bivalirudin), 31% reported bleeding, and 23% died (1 patient of heart failure and 2 of pulmonary embolism). Patients with no bleeding were generally treated by stopping the drug. Most of the patients with bleeding with a diagnosis of heparin-induced thrombocytopenia were undergoing cardiopulmonary bypass using the direct thrombin inhibitor bivalirudin. All of these patients were treated with blood products during surgery. The inpatients not receiving warfarin with thrombosis and INR higher than 9 were receiving a direct thrombin inhibitor or fibrinolytic therapy, 33% reported bleeding while 11% died. Typically they were treated with a combination of stopping the drug and blood products.
Diagnosis, Bleeding, and Treatment in Patients Receiving Warfarin
Of the patients receiving warfarin who had an INR higher than 9, 44% were outpatients. Of these, 11% reported bleeding that was typically treated with vitamin K. Outpatients with INR higher than 9 who did not have bleeding were treated by withholding warfarin in 36% and vitamin K in 64%. Platelet counts were available on 17 of 36 outpatients with INR higher than 9, all of which were normal (328 ± 125 ×10 3 /µL [328 ± 125 ×10 9 /L]). Follow-up on the outpatients was limited, but none died soon after the high INR was noted and none received blood products.
The association between common comorbidities and bleeding for all 82 patients receiving warfarin with INR higher than 9 is shown in ❚Table 3❚. The factors associated with an increased risk of bleeding were older age, the presence of renal failure, and alcohol use. In contrast, a history of cancer was associated with a reduced risk of bleeding.
Treatment of Inpatients Receiving Warfarin With INR Higher Than 9
Sixteen of the 46 inpatients receiving warfarin with INR higher than 9 were admitted for bleeding, whereas the other 30 patients were admitted for other reasons including infection or sepsis, thrombosis, cancer, and congestive heart failure ❚Table 4❚. Platelet counts were available on all inpatients with INR higher than 9 (232 ± 98 × 10 3 /µL [232 ± 98 × 10 9 /L]). Only 3 inpatients with INR higher than 9 had platelet counts less than 100 × 10 3 /µL (100 × 10 9 /L), of whom only 1 had bleeding (retroperitoneal hemorrhage associated with an abdominal aortic aneurysm). Overall mortality was 17% for the inpatients receiving warfarin with INR higher than 9. ❚Figure 1❚ shows the effect of different forms of treatment on inpatients taking warfarin who had an INR higher than 9. There was no difference in the initial INR for the 3 treatment groups (withholding warfarin, vitamin K administration, and plasma infusion). On average, patients treated with vitamin K were given 5 mg (range, 1-10 mg). On average, patients treated with plasma were given 4 units of fresh frozen plasma (range, 2-6 units). There was no significant difference in the INR after 24 hours of treatment between withholding warfarin and vitamin K administration (P = .20). Infusion of plasma significantly reduced the INR compared with vitamin K or withholding warfarin (P < .001).
Among the inpatients receiving warfarin with INR higher than 9 and bleeding at admission, 1 was treated by withholding warfarin (6%), 2 were treated with vitamin K (13%), and 13 received plasma infusion (81%). None of these patients experienced rebleeding and there were no deaths related to INR, international normalized ratio; NS, not significant. * Thrombosis included ischemic stroke (n = 5) and limb ischemia (n = 1).
bleeding episodes. For inpatients receiving warfarin with INR higher than 9 but no bleeding at admission, treatment included withholding warfarin in 3 (10%), vitamin K in 17 (57%), and plasma infusion in 10 (33%). There was 1 episode of fatal intracranial hemorrhage in the vitamin K group in a patient with INR higher than 9 after treatment.
Discussion
Supratherapeutic INR is a common occurrence in patients receiving warfarin treatment. 19 Garcia et al 11 showed that the risk of major bleeding in outpatients with an INR of 5 to 9 was 0.5% in the first 2 weeks, compared with 10% when the INR was higher than 9. Crowther et al 10 reported that up to 21% of patients with INR higher than 9 experienced bleeding within the next 7 days.
In this study, we evaluated 162 patients with INR higher than 9 during a 17-month period. We separated our data into 2 major groups, patients with INR higher than 9 who were either receiving warfarin or not receiving warfarin. We further separated the group not receiving warfarin into those receiving another anticoagulant or fibrinolytic drug vs those not taking any other antithrombotic medications. For outpatients (all receiving warfarin), the incidence of bleeding was 11%, similar to the rate seen in prior studies. 11 The incidence of bleeding in all patients with INR higher than 9 was 38%, higher than in previous studies. This difference reflects the inclusion of hospitalized patients with INR higher than 9, including patients receiving warfarin, those receiving other anticoagulants, and those receiving no anticoagulants. Prior studies have reported that older age was a risk factor for bleeding with warfarin therapy and that alcohol use was associated with an increased risk of intracranial hemorrhage. 9, 20 We found that in patients with INR higher than 9 who were receiving warfarin, older age, renal failure, and alcohol use were all associated with an increased risk of bleeding.
Patients with INR higher than 9 not receiving warfarin or any other anticoagulants generally had a severe underlying illness, typically shock after resuscitation for cardiac arrest, severe trauma, liver failure, or liver transplantation. These patients had a high rate of bleeding (67%), were typically treated with plasma infusion, and had a high mortality rate (74%). Although bleeding was common in this group, patients typically died of other causes. The other group of patients with INR higher than 9 and not receiving warfarin were patients receiving direct thrombin inhibitors or fibrinolytic therapy. Bleeding was still common in this group (32%), but the mortality rate was lower (18%). Prolonged INR in patients receiving direct thrombin inhibitors may be because of a combination of direct thrombin inhibitor effects and low factor levels. Determining the specific cause of INR higher than 9 in patients receiving direct thrombin inhibitors requires separate specific tests for both direct thrombin inhibitor effect that is not affected by low factor levels, such as a plasma diluted thrombin time, and for factor levels not affected by direct thrombin inhibitors, such as a chromogenic factor X level. [21] [22] [23] Vitamin K can successfully correct an excess of anticoagulation; the response depends on the dose of vitamin K and on the presence of normal liver function. Previous studies evaluating vitamin K response typically included only outpatients and often excluded patients with renal and liver dysfunction. 10, [13] [14] [15] [16] [17] In this study, we tracked the effect of treatment for INR higher than 9 in hospitalized patients receiving warfarin. We found that withholding warfarin had no effect on INR in the first 24 hours and that treatment with vitamin K produced a small decrease in INR by 24 hours, but that the effect was highly variable among patients and that the INR at 24 hours was not significantly different from withholding warfarin. A prior study on outpatients receiving VKA with INR higher than 10 used INR of less than 5 as a indication of successful treatment with vitamin K. 14 Using this criterion, withholding warfarin was unsuccessful at reversing INR higher than 9 for inpatients and vitamin K was successful in only 8 (42%) of 19 patients. In contrast, infusion of plasma produced an immediate decrease in INR, with significantly lower INR at 24 hours than did withholding warfarin or vitamin K administration. All of the patients with INR higher than 9 treated with plasma had an INR less than 5 after treatment (mean INR, 2.4). Conclusions from this study are limited by the observational and not randomized prospective nature of the data, lack of protocol for treatment decisions made by individual physicians, and potential influence of confounding variables. 
